Celyad Oncology S.A.
CYAD
Rang în acțiuni
#31627
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Preț acțiune
$0.25502336
Ultima sincronizare: 2026-10-16
Capitalizare de piață
$12.05M
Schimbare (1 zi)
0.47%
Schimbare (1 an)
-45.74%
Țară
BE
Tranzacționează Celyad Oncology S.A. (CYAD)
Categorie
Healthcare
Capitalizarea de piață a Celyad Oncology S.A.(CYAD)
Capitalizare de piață: $12.05M
În anul October 2026, Celyad Oncology S.A. are o capitalizare de piață de $12.05M. Acest lucru face ca Celyad Oncology S.A. să fie a 31627th-a cea mai valoroasă companie din lume, conform datelor noastre. Capitalizarea bursieră reprezintă valoarea totală de piață a acțiunilor în circulație ale unei companii listate și este utilizată frecvent pentru a măsura valoarea unei companii.
Istoricul capitalizării de piață a Celyad Oncology S.A. din 2015 până în 2026
CYAD în comparație cu top 5 cele mai populare stocks
